Wells Fargo & Company MN reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 34.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 329,616 shares of the biopharmaceutical company’s stock after selling 171,910 shares during the period. Wells Fargo & Company MN owned about 0.38% of Alnylam Pharmaceuticals worth $26,290,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. CIBC Asset Management Inc bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $221,000. Neuberger Berman Group LLC bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $229,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $148,000. Capstone Asset Management Co. bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $232,000. Finally, Hemenway Trust Co LLC bought a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $235,000. Institutional investors and hedge funds own 94.25% of the company’s stock.

A number of research analysts have commented on ALNY shares. Chardan Capital set a $110.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, June 12th. Needham & Company LLC increased their price target on shares of Alnylam Pharmaceuticals from $68.00 to $98.00 and gave the company a “buy” rating in a research report on Tuesday, June 27th. Jefferies Group LLC reiterated a “buy” rating and set a $102.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, June 22nd. BidaskClub cut shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 29th. Finally, Credit Suisse Group set a $96.00 price target on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, July 11th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $93.11.

WARNING: “Wells Fargo & Company MN Sells 171,910 Shares of Alnylam Pharmaceuticals, Inc. (ALNY)” was posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/09/23/wells-fargo-company-mn-sells-171910-shares-of-alnylam-pharmaceuticals-inc-alny.html.

Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) opened at 113.80 on Friday. The firm’s 50-day moving average price is $81.14 and its 200 day moving average price is $69.12. The stock’s market cap is $10.44 billion. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $118.40. Alnylam Pharmaceuticals also was the target of unusually large options trading on Wednesday. Stock investors acquired 30,530 call options on the stock. This represents an increase of 937% compared to the typical volume of 2,944 call options.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.12). Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The firm had revenue of $15.93 million during the quarter, compared to analysts’ expectations of $23.86 million. During the same quarter in the prior year, the company posted ($1.05) earnings per share. Alnylam Pharmaceuticals’s quarterly revenue was up 82.9% compared to the same quarter last year. On average, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($5.19) earnings per share for the current year.

In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of the company’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total value of $7,681,500.00. Following the completion of the sale, the president now directly owns 165,399 shares in the company, valued at approximately $16,539,900. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.30% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.